FDA Approves New Labeling for BMS' Sustiva Describing Long-Term Durability in Treatment-Naive Patients
August 30, 2004
FDA on Thursday approved new labeling for Bristol Myers Squibb's antiretroviral drug Sustiva that describes data from a recent clinical trial showing that the drug is effective at suppressing HIV in people who have taken a Sustiva-containing regimen for three years, the Associated Press reports. In the three-and-a-half year study -- which included 1,266 treatment-naïve, HIV-positive people -- subjects were randomized into three groups: the first group took Sustiva, zidovudine and lamivudine; the second took Sustiva, indinavir and lamivudine; and the third took indinavir, zidovudine and lamivudine. At the end of the study, 48% of patients in the first group had an HIV-1 RNA viral load below 400 copies per milliliter, compared with 40% in the second group and 29% in the third group. The study also found that 43% of patients in the first group had a viral load below 50 copies per milliliter, compared with 31% in the second group and 23% in the third (Associated Press, 8/26). "With this new labeling, health care professionals now have additional information to draw on when creating a durable antiretroviral regimen for their treatment-naïve patients," Anthony Hooper, BMS president of U.S. pharmaceuticals, said (BMS release, 8/26).
Bollywood Film on HIV/AIDS Opens to Mixed Reviews, Could Represent Ideological Shift on HIV/AIDS in India
China Passes Legislation to Ban Sale of Blood, Prevent Discrimination as Part of HIV Prevention Plan
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.